For tissue sections sensitive staining techniques are recommended, such as the LSABO+or the EnVision M+ systems The antibody may be used at a dilution of 1: 25-1: 50 with the LSAB@+ system when tested on formalin-fixed, paraffin-embedded sections of human tonsil Frozen sections and cell smears Can be used for labelling acetone-fixed cryostat sections or for fixed cell smears. For staining cell smears, the APAAP method is recommended The antibody may be used at a dilution at 1: 25-1: 50 in the APAAP technique, when tested on acetone-fixed cryostat sections of human tonsil These are guidelines only, optimal dilutions should be determined by the individual laborator Automation: The antibody can be used on automated immunostaining systems References (1) Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D p21 is a universal inhibitor of cyclin kinases. Nature 1993: 366: 701-4 (2) El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression Cell 1993: 75: 817-25 (3) Steinman RA, Hoffman B, Iro A, Guillouf C, Liebermann DA, El-Houseini ME. Induction of p21 (WAF. 1/CIP1)during differentiation. Oncogene 1994: 9: 3389-96 (4) Li R, Waga S, Hannon GJ, Beach D, Stillman B Differential effects by the p21 CDK inhibitor on PCNA- dependent DNA replication and repair. Nature 1994: 371: 534-7 (5)Gorospe M, Cirielli C, Wang X, Seth P, Capogrossi MC, Holbrook NJ. p21 afl/cipl protects against p53- mediated apoptosis of human melanoma cells. Oncogene 1997: 14: 929-3 ham sT, Dugan MC, Joshi US, Chen YC, mith DW, et al. The clinical significance of nd p53 expression in pancreatic adenocarcinoma Cancer 1997: 80: 372-81 (7) Palazzo JP, Mercer WE, Kovatich AJ, McHugh M. Immunohistochemical localization of p21 AF1CP1 in normal, hyperplastic, and neoplastic uterine tissues. Hum Pathol 1997: 27: 60-6 (8) Stefanaki K, Rontogianni D, Kouvidou CH, Bolioti S, Delides G, Pantelidaki A, et al. Expression of p53 mdm2, p21/waf1 and bcl-2 proteins in thymomas. Histopathol 1997: 30: 549-55 (9) Ito Y, Kobayashi T, Takeda T, Komoike Y, Wakasugi E, Tamaki Y, et al. Expression of p21 (WAF 1/CIP1) rotein in clinical thyroid tissues. Br J Cancer 1996: 74: 1269-74 genotoxic agents in wild-type TP53 expressing breast primary tumours. Oncogene 1997; 14. 45-Donse to (10) Guillot C, Falette N, Paperin M-P, Courtois S, Gentil-Perret A, Treilleux l et al. p21 WAFlcP'resp (11)Erber R, Klein W, AndI T, Enders C, Born Al, Conradt C, et al. Aberrant p21 P1/AF1 protein accumulation head-and-neck cancer. Int J Cancer 1997: 74: 383-9 (12)Valassiadou KE, Stefanaki K, Tzar Datseris G, Georgoulias V, Melissas J,et al Immunohistochemical expression of p53, bcl-2, mdm2 adenocarcinomas Anticancer Res 1997: 17: 2571-6 (13)Naresh KN, O'Conor GT, Soman CS, Johnson J, Advani SH, Magrath IT, et al. a study of p53 protein odgkin's disease at presentation and relapse 1997;28:54955 (14)Fredersdorf S, Milne AW, Hall PA, Lu X Characterization of a panel of novel anti-p21 wati/ monoclonal antibodies and immunochemical analysis of p21 expression in nomal human tissues. Am J Pathol1996;148:825-35 M7202JA09.1100- 2 - For tissue sections sensitive staining techniques are recommended, such as the LSAB+ or the EnVision™+ systems. The antibody may be used at a dilution of 1:25 - 1:50 with the LSAB+ system when tested on formalin-fixed, paraffin-embedded sections of human tonsil. Frozen sections and cell smears Can be used for labelling acetone-fixed cryostat sections or for fixed cell smears. For staining cell smears, the APAAP method is recommended. The antibody may be used at a dilution at 1:25 - 1:50 in the APAAP technique, when tested on acetone-fixed cryostat sections of human tonsil. These are guidelines only; optimal dilutions should be determined by the individual laboratory. Automation: The antibody can be used on automated immunostaining systems. References (1) Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993;366:701-4. (2) El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25. (3) Steinman RA, Hoffman B, Iro A, Guillouf C, Liebermann DA, El-Houseini ME. Induction of p21 (WAF- 1/CIP1) during differentiation. Oncogene 1994;9:3389-96. (4) Li R, Waga S, Hannon GJ, Beach D, Stillman B. Differential effects by the p21 CDK inhibitor on PCNA￾dependent DNA replication and repair. Nature 1994;371:534-7. (5) Gorospe M, Cirielli C, Wang X, Seth P, Capogrossi MC, Holbrook NJ. p21Waf1/Cip1 protects against p53- mediated apoptosis of human melanoma cells. Oncogene 1997;14:929-35. (6) Dergham ST, Dugan MC, Joshi US, Chen YC, Du W, Smith DW, et al. The clinical significance of p21WAF1/CIP1 and p53 expression in pancreatic adenocarcinoma. Cancer 1997;80:372-81. (7) Palazzo JP, Mercer WE, Kovatich AJ, McHugh M. Immunohistochemical localization of p21WAF1/CIP1 in normal, hyperplastic, and neoplastic uterine tissues. Hum Pathol 1997;27:60-6. (8) Stefanaki K, Rontogianni D, Kouvidou CH, Bolioti S, Delides G, Pantelidaki A, et al. Expression of p53, mdm2, p21/waf1 and bcl-2 proteins in thymomas. Histopathol 1997;30:549-55. (9) Ito Y, Kobayashi T, Takeda T, Komoike Y, Wakasugi E, Tamaki Y, et al. Expression of p21 (WAF1/CIP1) protein in clinical thyroid tissues. Br J Cancer 1996;74:1269-74. (10) Guillot C, Falette N, Paperin M-P, Courtois S, Gentil-Perret A, Treilleux I, et al. p21 WAF1/CIP1 response to genotoxic agents in wild-type TP53 expressing breast primary tumours. Oncogene 1997;14:45-52. (11) Erber R, Klein W, Andl T, Enders C, Born AI, Conradt C, et al. Aberrant p21CIP1/WAF1 protein accumulation in head-and-neck cancer. Int J Cancer 1997;74:383-9. (12) Valassiadou KE, Stefanaki K, Tzardi M, Datseris G, Georgoulias V, Melissas J, et al. Immunohistochemical expression of p53, bcl-2, mdm2 and waf1/p21 proteins in colorectal adenocarcinomas. Anticancer Res 1997;17:2571-6. (13) Naresh KN, O’Conor GT, Soman CS, Johnson J, Advani SH, Magrath IT, et al. A study of p53 protein, proliferating cell nuclear antigen, and p21 in Hodgkin’s disease at presentation and relapse. Hum Pathol 1997;28:549-55. (14) Fredersdorf S, Milne AW, Hall PA, Lu X. Characterization of a panel of novel anti-p21Waf1/Cip1 monoclonal antibodies and immunochemical analysis of p21Waf1/Cip1 expression in normal human tissues. Am J Pathol 1996;148:825-35. M 7202/JA/09.11.00